title: Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma.
abstract: Tumor cells that have been genetically modified to express immunostimulatory genes will induce effective antitumor responses in a range of syngeneic animal models. For human applications, transduced autologous tumor cell lines are often difficult or impossible to prepare, so that there are strong incentives for substituting a standardized allogeneic tumor cell line. However, such lines may be inferior immunogens if they differ from host tumors in the antigens they express. We have evaluated the safety, immunostimulatory, and antitumor activity of an interleukin-2-secreting allogeneic neuroblastoma cell line in 12 children with relapsed stage IV neuroblastoma. They received two to four subcutaneous injections of cells in a dose-escalating schedule, up to a maximum of 10(8) cells per injection. There was induration and pruritus at the injection site, and skin biopsies revealed mild panniculitis with CD3+ cells surrounding scanty residual tumor cells. There was a limited but significant peripheral monocytosis. No patient showed any increase in direct cytotoxic effector function against the immunizing cell line, but 3 patients had a rise in the frequency of neuroblastoma-reactive cytotoxic T lymphocyte precursor cells. One child had > 90% tumor response (PR), 7 had stable disease, and 4 had progressive disease in response to vaccine alone. Although these results offer some encouragement for the continued pursuit of allogeneic vaccine strategies in human cancer, the antitumor immune responses we observed are inferior to those obtained in an earlier immunization study using autologous neuroblastoma cells. Hence, we suggest that this earlier approach remains preferable, its difficulties notwithstanding.
authors.affiliation: Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
authors.forename: L C
authors.initials: LC
authors.lastname: Bowman
authors.forename: M
authors.initials: M
authors.lastname: Grossmann
authors.forename: D
authors.initials: D
authors.lastname: Rill
authors.forename: M
authors.initials: M
authors.lastname: Brown
authors.forename: W Y
authors.initials: WY
authors.lastname: Zhong
authors.forename: B
authors.initials: B
authors.lastname: Alexander
authors.forename: T
authors.initials: T
authors.lastname: Leimig
authors.forename: E
authors.initials: E
authors.lastname: Coustan-Smith
authors.forename: D
authors.initials: D
authors.lastname: Campana
authors.forename: J
authors.initials: J
authors.lastname: Jenkins
authors.forename: D
authors.initials: D
authors.lastname: Woods
authors.forename: M
authors.initials: M
authors.lastname: Brenner
mesh_terms: D019496:Cancer Vaccines; D017690:Cell Transplantation; D002648:Child; D002675:Child, Preschool; D003602:Cytotoxicity, Immunologic; D015316:Genetic Therapy; D006801:Humans; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000096:biosynthesis* / Q000235:genetics*; D009447:Neuroblastoma / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D010641:Phenotype; D012008:Recurrence; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured
chemical_list: D019496:Cancer Vaccines; D007376:Interleukin-2